6/17/2014 6:38:27 AM
This week's tweet of the week comes from Patrick Crutcher of Chimera Research Group, who points out that if Bristol-Myers Squibb (NYSE: BMY ) becomes cheap enough, Pfizer (NYSE: PFE ) might be more interested in buying Bristol-Myers Squibb than it was in buying AstraZeneca (NYSE: AZN ) .
Bristol-Myers Squibb has seen a post-ASCO fall after investors were less than impressed with its immuno-oncology drugs. The pharma was priced at a premium, so it shouldn't be too surprising that any slip-up might result in a share-price drop.
Help employers find you! Check out all the jobs and post your resume.
comments powered by